Sonnet BioTherapeutics Holdings (SONN) has issued an update.
The Company has introduced two innovative immunotherapeutic drug candidates, SON-1411 and SON-1400, featuring a unique IL-18 variant. These drugs are designed to target tumors more effectively by evading the inhibitory effects of IL-18 Binding Protein and have shown promising bioactivity in receptor binding assays. SON-1411, a bifunctional fusion protein, advances the treatment strategy by incorporating IL-12 and aims to improve upon its predecessor, SON-1410. Both drugs leverage the Company’s proprietary technology to extend their half-life and target the tumor microenvironment, which could potentially enhance their therapeutic efficacy against cancer.
Find detailed analytics on SONN stock on TipRanks’ Stock Analysis page.
